02.09.23 -- 3 Themes For Gene Therapy In 2023

Learn how a project management process that works across disciplines can help coach, improve, and inspire others in that method to help them get the business value they need.

The collaboration between AAV gene therapy developers and CDMOs has resulted in scalable manufacturing solutions to develop biological therapeutics poised for successful patient outcomes and other commercialized treatments.

With industry-leading scientific expertise and customer support, we have pioneered solutions to some of the most pressing challenges facing customers interested in adopting MAM into their organizations.

Learn how to accelerate your clinical timeline for cell and gene therapies and improve next-generation GMP production facilities.

Despite its efficacy, electroporation is mistakenly underutilized because of the perceived initial up-front cost in purchasing an electroporator and its association with high cytotoxicity.

Learn about new data that highlights exciting uses for future immunotherapy studies.

A cell line development platform that enables the generation of producer cell lines (PCLs) directly in suspension, in accelerated timelines, has been successfully implemented.

Realizing the potential of mRNA requires focus on key areas and strategies that could help alleviate the bottlenecks in this growing market segment.

Sequencing techniques play a crucial role in establishing the quality attributes of a variety of therapeutic products. Learn what advantages NGS offers for obtaining accurate sequences.

Explore the unique capabilities at a Vancouver, Canada, site for clinical-scale manufacture of lipid nanoparticles (LNPs).

This application note demonstrates systems that have proven quite useful for clarification of mammalian cell cultures such as CHO cells by combining the cell clearance and sterile filtration functionality in a single device.

Listen as Kevin, senior regulatory strategist for Veristat, identifies some of the key components of a cell & gene therapy marketing application in the U.S. and EU and outlines several of the most common pitfalls and gaps that he has encountered with sponsor applications.

Hear about our venture into the development and manufacturing of viral vector gene therapies and how we are overcoming challenges and maintaining our commitment to our partners.

Learn more about manufacturing process guidelines from seed train to quality control/analytics for batch release.

Advanced therapies have been a significant disruptor in healthcare. Explore cutting-edge technologies, their effectiveness, and what we as a sector must still overcome to bring these treatments to the patient.